Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEMINI: Intranasal ALN-RSV01 in Healthy Volunteers Inoculated with RSV
NCT00496821Phase 2Completed
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Jul 2007
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in respiratory syncytial virus infection (RSV) comparing ALN-RSV01 with Placebo (2 arms). Primary endpoint: Safety and tolerability of intranasal ALN-RSV01 versus placebo at 28 days. Started Jul 2007; status: completed.
02
Drugs
asvasiran
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT00496821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00496821.